Runmaide medical opened the offering: without the participation of cornerstone investors, the amount of loss doubled

6 month 27 Japan , Runmaide -B（ namely “ Runmaide Medical ”, HK:02297） The announcement on the Hong Kong Stock Exchange said , Intended to be 2022 year 6 month 27 solstice 6 month 30 Daily offering , To issue 2334.8 Ten thousand shares , Among them, Hong Kong sales account for 10%, International sales account for 90%, Attached 15% Over allotment .

This issue , The offering price of runmaide medical is... Per share 4.28 HK $to HK $per share 6.24 The Hong Kong dollar , Every hand 1000 stocks , It is expected that 2022 year 7 month 8 Trading on the Hong Kong Stock Exchange began on the th . let me put it another way , Runmaide medical is expected to 7 month 8 Listing on the Hong Kong Stock Exchange , The maximum amount raised is about 1.5 Million Hong Kong dollars .

But Bedouin found that , Runmaide medical has not been subscribed by cornerstone investors in this offering . by comparison , Zhiyun health, which belongs to the same medical industry （HK:09955） Then introduce 4 A cornerstone investor , Total subscription is about 4500 Thousands of dollars . among , The offering price of Zhiyun health is 30.5 The Hong Kong dollar / stocks , Most fundraising 5.8 Million Hong Kong dollars .

This means to some extent , Investors are not optimistic about the growth space of runmaide medical .

Before that , Runmaide medical has completed Angel-1 round 、Angel-2 round 、A+ round 、B round 、C-1 round 、C-2 Wheel and D Round of funding . It's just 2021 year 9 month , Runmaide medical has announced the completion of 7200 Ten thousand dollar financing , Ping An capital, the core private equity platform of Ping An, China, leads the investment ,Seresia Asset Management、Lighthouse Canton Wait for the follow-up shot .

Before this IPO , Ping An investment holds 6.29%; Executive director of runmaide Medical 、 Huoyunfei, chairman of the board of directors and chief executive officer, passed Opera Rose holding 18.77%, His brother huoyunlong passed Vermilion Bird holding 13.98%, total 32.75%; Lvyonghui, executive director and co CEO of runmaide medical, passed the Mingze holding 2.70%.

meanwhile , Gu Yang, executive director and vice president of runmaide medical, passed ASHG HK holding 0.47%, Executive director 、 Zhang Liang, chief financial officer and co Secretary of the company, passed ANC HK holding 0.39%, Liuguangzhi, chief technology officer, holds the shares AIMEI holding 1.66%, Wu Xingyun, vice president, holds shares 1.24%, LiuKangJian, vice president and Secretary of the board of directors, passed NEXT DAWN holding 0.39%.

According to the prospectus , Runmaide medical was founded in 2014 year , Is a medical device company , The current focus is on the fractional flow reserve system for coronary angiography （“caFFR System ”） And coronary angiography microvascular resistance index system （“caIMR System ”） The design of the 、 Development and commercialization .

The track record period , Runmaide medical is 2019 year 10 month caFFR The commercialization of the system begins to generate revenue . By 2020 Years and 2021 year 12 month 31 End of day year , Runmaide medical recorded revenue respectively （ income ） RMB 609.7 Ten thousand yuan 、8119.9 Ten thousand yuan , A net loss （ Loss during the year ） Respectively 1.45 Million dollars 6.34 One hundred million yuan .

Runmaide medical explained in the prospectus that , Mainly due to (i) The fair value loss of financial liabilities increased significantly , Mainly due to 2021 The group's valuation rose in , The fair value of the preferred shares increases accordingly and (ii) General and administrative expenses and sales expenses increased significantly , Mainly due to the fact that the company 2021 Share awards granted in .

Under non HKFRS measurement , Runmaide Medical 2020 year 、2021 Net adjusted loss for the year （ Without audit ） Respectively 2699.0 Ten thousand yuan 、5168.5 Ten thousand yuan . By 2021 year 12 month 31 Japan , The net debt of runmaide medical is 7.75 One hundred million yuan , Cash and cash equivalents are 5.59 One hundred million yuan .

Runmaide medical also said in the prospectus , It is expected that 2022 The net loss for the year will increase , This is mainly because runmaide medical is expected to provide funds for the ongoing and future clinical trials of its core products and the preclinical research of other products under development , Will continue to generate significant R & D expenditures .

The same as runmaide medical treatment is , The loss amount of Zhiyun health is also good .2019 year 、2020 Years and 2021 year , The income of Zhiyun health is 5.24 One hundred million yuan 、8.39 Million dollars 17.57 One hundred million yuan ; Net losses are 5.65 One hundred million yuan 、28.97 Million dollars 41.53 One hundred million yuan , The adjusted net losses were 1.50 One hundred million yuan 、6.36 Million dollars 4.44 One hundred million yuan .

According to frost Sullivan report , On 2020 year , In terms of income , Zhiyun health ranks second in the digital marketing service market for Chinese pharmaceutical and medical device companies , The market share is 10.9%. At the same time , Medical pulse is clear （HK:02192）、 Medivac （HK:02159） Respective proportion 11.6%、6.5%.